Dallas, Texas--(Newsfile Corp. - May 2, 2024) - Stonegate Healthcare Partners is providing an update on the publication of its report, titled "Transformative Therapies for Pruritus Management." This comprehensive report delves into the critical issue of pruritus, or chronic itch, and its impact on patients, particularly those suffering from Primary Biliary Cholangitis (PBC), an autoimmune liver disease.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
Stonegate Healthcare Partners identifies leading programs aiming to reshape the landscape of pruritus treatment and significantly improve patients' quality of life.
Companies featured in the report include Connect Biopharma (NASDAQ: CNTB), Ironwood Pharmaceuticals (NASDAQ: IRWD), Mirum Pharmaceuticals (NASDAQ: MIRM), and Tharimmune (NASDAQ: THAR).
Click image above to view full announcement.
About Stonegate Healthcare Partners
Our mission at Stonegate Healthcare Partners is to accelerate meaningful innovations in healthcare through Strategy, Market Intelligence, Business Development, and Investor Outreach. The firm's research approach is centered on comprehensive and comparative analyses in specific healthcare fields. We strive to pinpoint programs that align closely with our strategic vision for the space and focus on technologies with the greatest potential for disruption. Stonegate Healthcare builds on its foundational thematic research by continuously gathering market intelligence, further enabling a current understanding of unmet needs and emerging disruptive technologies.
Contacts:
Shiv Kapoor
shiv@stonegateinc.com
Distributed by: Reportable, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/207789
